Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 6
2001 6
2002 4
2003 4
2004 9
2005 9
2006 14
2007 10
2008 8
2009 7
2010 6
2011 5
2012 4
2013 4
2014 7
2015 5
2016 4
2017 3
2019 2
2020 3
2021 2
2022 4
2023 3
2024 5
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

125 results

Results by year

Filters applied: . Clear all
Page 1
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
Pérez-García JM, Cortés J, Ruiz-Borrego M, Colleoni M, Stradella A, Bermejo B, Dalenc F, Escrivá-de-Romaní S, Calvo Martínez L, Ribelles N, Marmé F, Cortés A, Albacar C, Gebhart G, Prat A, Kerrou K, Schmid P, Braga S, Di Cosimo S, Gion M, Antonarelli G, Popa C, Szostak E, Alcalá-López D, Gener P, Rodríguez-Morató J, Mina L, Sampayo-Cordero M, Llombart-Cussac A; PHERGain Trial Investigators. Pérez-García JM, et al. Among authors: kerrou k. Lancet. 2024 Apr 27;403(10437):1649-1659. doi: 10.1016/S0140-6736(24)00054-0. Epub 2024 Apr 3. Lancet. 2024. PMID: 38582092 Clinical Trial.
Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023.
Gligorov J, Benderra MA, Barthere X, de Forceville L, Antoine EC, Cottu PH, Delaloge S, Pierga JY, Belkacemi Y, Houvenaegel G, Pujol P, Rivera S, Spielmann M, Penault-Llorca F, Namer M; et l'ensemble des experts des votes des RPC Saint-Paul 2022-2023. Gligorov J, et al. Bull Cancer. 2023 Nov;110(10S):10S1-10S43. doi: 10.1016/S0007-4551(23)00473-3. Bull Cancer. 2023. PMID: 38061827
Mpox Hepatic and Pulmonary Lesions in HIV/Hepatitis B Virus Co-Infected Patient, France.
Calin R, Périllaud-Dubois C, Marot S, Kerrou K, Peytavin G, Bachir M, Kirch AL, Lassel L, Fallet V, Gozlan J, Pain JB, Senet P, Ferraris O, Bine S, Hubert M, Schwartz O, Morand-Joubert L, Pialoux G. Calin R, et al. Among authors: kerrou k. Emerg Infect Dis. 2024 Nov;30(11):2445-2447. doi: 10.3201/eid3011.241331. Emerg Infect Dis. 2024. PMID: 39447209 Free PMC article.
[Functional chest imaging].
Carette MF, Kerrou K, Khalil A. Carette MF, et al. Among authors: kerrou k. Rev Pneumol Clin. 2005 Oct;61(5 Pt 1):291-5. doi: 10.1016/s0761-8417(05)84842-4. Rev Pneumol Clin. 2005. PMID: 16292153 Review. French. No abstract available.
[PET and malignant cerebral tumors].
Talbot JN, Kerrou K, Gault N, Gutman F, Grahek D, Touboul E, Schlienger M, Montravers F. Talbot JN, et al. Among authors: kerrou k. Presse Med. 2006 Sep;35(9 Pt 2):1347-53. doi: 10.1016/s0755-4982(06)74818-7. Presse Med. 2006. PMID: 16969331 Review. French.
Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.
Gebhart G, Keyaerts M, Guiot T, Flamen P, Ruiz-Borrego M, Stradella A, Bermejo B, Escriva-de-Romani S, Calvo Martínez L, Ribelles N, Fernandez-Abad M, Albacar C, Colleoni M, Garrigos L, Atienza de Frutos M, Dalenc F, Prat A, Marmé F, Schmid P, Kerrou K, Braga S, Gener P, Sampayo-Cordero M, Cortés J, Pérez-García JM, Llombart-Cussac A. Gebhart G, et al. Among authors: kerrou k. J Nucl Med. 2024 May 1;65(5):708-713. doi: 10.2967/jnumed.123.266384. J Nucl Med. 2024. PMID: 38575192 Free article.
18F-Fluorocholine-Positron Emission Tomography/Computerized Tomography (FCH PET/CT) Imaging for Detecting Abnormal Parathyroid Glands: Indication, Practice, Interpretation and Diagnostic Performance.
Noskovicova L, Balogova S, Aveline C, Tassart M, Zhang-Yin J, Kerrou K, Jaksic I, Montravers F, Talbot JN. Noskovicova L, et al. Among authors: kerrou k. Semin Nucl Med. 2024 Nov;54(6):875-895. doi: 10.1053/j.semnuclmed.2024.08.002. Epub 2024 Sep 20. Semin Nucl Med. 2024. PMID: 39306520
[PET in head and neck cancers].
Talbot JN, Périé S, Kerrou K, Montravers F, Balogova S, Grahek D, Gutman F, Saint Guily JL. Talbot JN, et al. Among authors: kerrou k. Presse Med. 2006 Sep;35(9 Pt 2):1355-69. doi: 10.1016/s0755-4982(06)74819-9. Presse Med. 2006. PMID: 16969332 Review. French.
Neglected giant benign phyllode tumor of the breast.
Benderra MA, Ferrier C, Buob D, Gligorov J, Kerrou K. Benderra MA, et al. Among authors: kerrou k. Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3954-3955. doi: 10.1007/s00259-022-05840-7. Epub 2022 May 18. Eur J Nucl Med Mol Imaging. 2022. PMID: 35583825 Free PMC article. No abstract available.
125 results